Monoclonal antibody specific to a common determinant site of neutrophilsand eosinophils

Abstract From the Canadian patent

A hybrid cell line capable of producing monoclonal antibodies uniquely specific to human neutrophils and eosinophils and exhibiting no specificity for lymphocytes basophils and monocytes. Further there is no reactivity with acute leukemia cells. One of the partners in the hybridoma fusion of a mouse spleen cell developed from using human granulocytes as the immunization agent. The monoclonal antibody further is capable of being used to enumerate and isolate neutrophils in normal peripheral blood and possibly in blood of patients with acute leukemia.